SK Bioscience "Confirmed Immunogenicity in Phase 3 Clinical Trial Results of COVID-19 Vaccine"

[Asia Economy Reporter Ji Yeon-jin] SK Bioscience announced on the 22nd that it confirmed high immunogenicity meeting all Immunobridging criteria after primary vaccination in the Phase 3 clinical trial results of the COVID-19 vaccine (GBP510).

The company stated, "It can be estimated to have vaccine efficacy equal to or greater than the high preventive effect confirmed with the AstraZeneca vaccine," adding, "We plan to proceed with domestic and overseas approval applications for the indication of COVID-19 disease prevention after primary vaccination with the GBP510 vaccine in adults by securing additional safety results."

This content was produced with the assistance of AI translation services.